Le Lézard
Classified in: Health

Dr. Bobbak "Bobby" Mansouri to join U.S. Dermatology Partners Tyler


TYLER, Texas, June 17, 2019 /PRNewswire-PRWeb/ -- Dr. Bobbak "Bobby" Mansouri will begin treating patients at U.S. Dermatology Partners Tyler and Lindale June 17th.

Dr. Mansouri is a board-certified dermatologist specializing in the diagnosis and treatment of disorders of the hair, skin, and nails. He has a special interest in the diagnosis and treatment of psoriasis and skin cancer and has served as an expert consultant nationally and internationally in the field of psoriasis.

Dr. Mansouri graduated with the distinction of Highest Ranking Graduate from Texas Tech University after serving four years as a Howard Hughes Medical Institute Undergraduate Research Scholar and being awarded the nationally recognized Barry M. Goldwater Scholarship for undergraduates pursuing careers in medicine and research. Dr. Mansouri obtained his medical degree from Duke University School of Medicine, during which time he completed a Clinical Research Training Program fellowship at the National Institutes of Health in Bethesda, MD. He then completed a transitional year internship at the University of Pittsburgh Medical Center's Mercy Hospital.

Dr. Mansouri spent two and half years completing research fellowship training in clinical trials under the direction of the internationally renowned psoriasis expert, Dr. Alan Menter, at Baylor University Medical Center in Dallas, TX. Dr. Mansouri completed his dermatology residency training at Texas A&M College of Medicine ? Baylor Scott and White Hospital in Temple, TX, where he served as the Chief Resident in his final year.

He has published over 20 research articles, has presented his work at national and international conferences, and is a reviewer for multiple high impact dermatology research journals. Dr. Mansouri has special interests in both patient education and medical education. He is active on social media and hopes to use these platforms as a means to expand dermatologic education for patients and providers alike.

Dr. Mansouri was raised in Lubbock, TX, and he is no stranger to the effects of the Texas sun on patients' skin, especially in the summertime. He enjoys cooking, karaoke, and sports.

About U.S. Dermatology Partners
As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatment through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team therefore includes recognized national leaders in areas such as clinical research, psoriasis and Mohs Surgery. To learn more, visit usdermatologypartners.com.

 

SOURCE U.S. Dermatology Partners


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: